Is Estrella Immunopharma, Inc. (ESLA) a Buy, Sell, or Hold?
NASDAQ : ESLA
Estrella Immunopharma, Inc.
$0.7585 USD
$0.04 (4.98%)
- Volume
- 13.27K
- Average Volume
- 39.19K
- Market Capitalization
- $32.36M
- P/E Ratio
- -2.19
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.15
- Year Low
- $0.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.24
Company Overview
NASDAQ
Cheng Liu
Biotechnology
Healthcare
ESLA
3
US
USD
Liquidity Metrics
0.00
0.24
0.24
0.22
0.00
Sales & Valuation
-$
0.00
-6.06
-4.04
-0.19
Profitability
-$0.35
-$13.06M
0.00%
0.00%
167.91%
-362.33%
P/E Metrics
-2.19
0.11
0.11
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-27.14
2/9
-$6.77M
$3.66M
$8.93M
-$13.25M
Key Metrics (TTM)
$28.9M
0.00
-2.18
0.24
167.91%
251.42%
-43.54%
-26.01%
0 days
Company Executives
| Name | Title |
|---|---|
| Jiandong Xu | Chief Financial Officer |
| Cheng Liu | Chief Executive Officer, President & Director |
Poll Results
No votes yet today — be the first to share your view!
About Estrella Immunopharma, Inc. (NASDAQ:ESLA) Stock
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California. ...
2026-08-03 08:00:00
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin's lymph.
2026-07-29 08:00:00
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin's lymp.
2026-07-24 08:00:00
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractor.
Frequently Asked Questions
-
What is the current Estrella Immunopharma, Inc. (ESLA) stock price?
-
Estrella Immunopharma, Inc.(NASDAQ:ESLA) stock price is $0.7585 in the last trading session. During the trading session, ESLA stock reached the peak price of $3.15 while $0.678 was the lowest point it dropped to. The percentage change in ESLA stock occurred in the recent session was 4.98% while the dollar amount for the price change in ESLA stock was $0.04.
-
ESLA's industry and sector of operation?
-
The NASDAQ listed ESLA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ESLA?
-
Jiandong Xu | Chief Financial Officer
Cheng Liu | Chief Executive Officer, President & Director
|
|
| -
How many employees does ESLA have?
-
Number of ESLA employees currently stands at 3. ESLA operates from 5858 Horton Street, EmeryVille, CA 94608, US.
-
Link for ESLA official website?
-
Official Website of ESLA is: https://www.estrellabio.com
-
How do I contact ESLA?
-
ESLA could be contacted at phone #510 318 9098 and can also be accessed through its website. ESLA operates from 5858 Horton Street, EmeryVille, CA 94608, US.
-
How many shares of ESLA are traded daily?
-
The average number of ESLA shares traded daily for last 3 months was 39.19K.
-
What is the market cap of ESLA currently?
-
The market value of ESLA currently stands at $32.36M with its latest stock price at $0.7585